Dual-targeted therapies boost BRAF response
This is a BRAF news story, published by ScienceDaily, that relates primarily to Van Cutsem news.
BRAF news
For more BRAF news, you can click here:
more BRAF newsVan Cutsem news
For more Van Cutsem news, you can click here:
more Van Cutsem newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsScienceDaily news
For more news from ScienceDaily, you can click here:
more news from ScienceDailyAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
mutant metastatic colorectal cancer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest mutant colorectal cancer news, Clinical Oncology Gastrointestinal Cancers news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
mFOLFOX6 chemotherapy regimenScienceDaily
•Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
82% Informative
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF -mutated metastatic colorectal cancer Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations.
The findings were presented today at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI ) Annual Symposium.
Story Source: Journal Reference: - Kopetz, S. , Yoshino , T. , Van Cutsem , E. et al . Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med , 2025 DOI: 10.1038 /s41591-024-03443-3 Cite This Page:.
VR Score
91
Informative language
98
Neutral language
65
Article tone
formal
Language
English
Language complexity
78
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links